Relationship Between Heart Disease and Liver Disease: A Two-Way Street

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2020 Mar 4

PMID 32121065

Citations 53

Authors

Hamza El Hadi

Angelo Di Vincenzo

Roberto Vettor

Marco Rossato

Affiliations

Soon will be listed here.

Abstract

In clinical practice, combined heart and liver dysfunctions coexist in the setting of the main heart and liver diseases because of complex cardiohepatic interactions. It is becoming increasingly crucial to identify these interactions between heart and liver in order to ensure an effective management of patients with heart or liver disease to provide an improvement in overall prognosis and therapy. In this review, we aim to summarize the cross-talk between heart and liver in the setting of the main pathologic conditions affecting these organs. Accordingly, we present the clinical manifestation, biochemical profiles, and histological findings of cardiogenic ischemic hepatitis and congestive hepatopathy due to acute and chronic heart failure, respectively. In addition, we discuss the main features of cardiac dysfunction in the setting of liver cirrhosis, nonalcoholic fatty liver disease, and those following liver transplantation.

Citing Articles

Hepatokines and their role in cardiohepatic interactions in heart failure.

Shouman W, Najmeddine S, Sinno L, Dib Nehme R, Ghawi A, Ziade J Eur J Pharmacol. 2025; 992:177356.

PMID: 39922419 PMC: 11862882. DOI: 10.1016/j.ejphar.2025.177356.

MeQTL Mapping in African American Hepatocytes Reveals Shared Genetic Regulators of DNA Methylation and Gene Expression.

Carver K, Clark C, Zhong Y, Yang G, Mishra M, Alarcon C bioRxiv. 2025; .

PMID: 39896509 PMC: 11785176. DOI: 10.1101/2025.01.23.634506.

Therapeutic effect of coenzyme-Q10 pretreatment on isoprenaline-induced cardiogenic hepatorenal complications in rats.

Chidebe E, Moke E, Asiwe J, Ben-Azu B, Demaki W, Oritsemuelebi B Int J Physiol Pathophysiol Pharmacol. 2025; 16(6):126-137.

PMID: 39850246 PMC: 11751547. DOI: 10.62347/PFXZ9903.

The impact of a humanized bile acid composition on atherosclerosis development in hypercholesterolaemic Cyp2c70 knockout mice.

Yntema T, Eijgenraam T, Kloosterhuis N, Havinga R, Koster M, Hovingh M Sci Rep. 2025; 15(1):2100.

PMID: 39815082 PMC: 11735988. DOI: 10.1038/s41598-025-86183-9.

Prevalence and associated factors of MAFLD in adults with type 2 diabetes.

He Y, Xiao F, Yi B, Lu J PLOS Glob Public Health. 2025; 4(12):e0003572.

PMID: 39775020 PMC: 11684647. DOI: 10.1371/journal.pgph.0003572.

References

Goldberg D, Fallon M . The Art and Science of Diagnosing and Treating Lung and Heart Disease Secondary to Liver Disease. Clin Gastroenterol Hepatol. 2015; 13(12):2118-27. PMC: 4618073. DOI: 10.1016/j.cgh.2015.04.024. View

Sehgal L, Srivastava P, Pandey C, Jha A . Preoperative cardiovascular investigations in liver transplant candidate: An update. Indian J Anaesth. 2016; 60(1):12-8. PMC: 4782417. DOI: 10.4103/0019-5049.174870. View

Polimeni L, Ben M, Baratta F, Perri L, Albanese F, Pastori D . Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World J Hepatol. 2015; 7(10):1325-36. PMC: 4450196. DOI: 10.4254/wjh.v7.i10.1325. View

Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S . Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2014; 61(5):1547-54. DOI: 10.1002/hep.27368. View

Shen Y, Ma X, Zhou J, Pan X, Hao Y, Zhou M . Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol. 2013; 12:124. PMC: 3766150. DOI: 10.1186/1475-2840-12-124. View

Mahfood Haddad T, Hamdeh S, Kanmanthareddy A, Alla V . Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis. Diabetes Metab Syndr. 2016; 11 Suppl 1:S209-S216. DOI: 10.1016/j.dsx.2016.12.033. View

Birrer R, Takuda Y, Takara T . Hypoxic hepatopathy: pathophysiology and prognosis. Intern Med. 2007; 46(14):1063-70. DOI: 10.2169/internalmedicine.46.0059. View

Sherlock S . The liver in heart failure; relation of anatomical, functional, and circulatory changes. Br Heart J. 1951; 13(3):273-93. PMC: 479419. DOI: 10.1136/hrt.13.3.273. View

Grueter C, Van Rooij E, Johnson B, DeLeon S, Sutherland L, Qi X . A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell. 2012; 149(3):671-83. PMC: 3340581. DOI: 10.1016/j.cell.2012.03.029. View

10.

Hendrickse M, Triger D . Peripheral and cardiovascular autonomic impairment in chronic liver disease: prevalence and relation to hepatic function. J Hepatol. 1992; 16(1-2):177-83. DOI: 10.1016/s0168-8278(05)80112-6. View

11.

Moller S, Henriksen J . Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart. 2001; 87(1):9-15. PMC: 1766971. DOI: 10.1136/heart.87.1.9. View

12.

Albeldawi M, Aggarwal A, Madhwal S, Cywinski J, Lopez R, Eghtesad B . Cumulative risk of cardiovascular events after orthotopic liver transplantation. Liver Transpl. 2011; 18(3):370-5. DOI: 10.1002/lt.22468. View

13.

Basu P, Aloysius M, Shah N, Brown Jr R . Review article: the endocannabinoid system in liver disease, a potential therapeutic target. Aliment Pharmacol Ther. 2014; 39(8):790-801. DOI: 10.1111/apt.12673. View

14.

Haukeland J, Dahl T, Yndestad A, Gladhaug I, Loberg E, Haaland T . Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. Eur J Endocrinol. 2011; 166(3):503-10. DOI: 10.1530/EJE-11-0864. View

15.

Liu H, Ma Z, Lee S . Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology. 2000; 118(5):937-44. DOI: 10.1016/s0016-5085(00)70180-6. View

16.

Mantovani A, Zoppini G, Targher G, Golia G, Bonora E . Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals. J Endocrinol Invest. 2012; 35(2):215-8. DOI: 10.1007/BF03345421. View

17.

Baik S, Fouad T, Lee S . Cirrhotic cardiomyopathy. Orphanet J Rare Dis. 2007; 2:15. PMC: 1847677. DOI: 10.1186/1750-1172-2-15. View

18.

Bolognesi M, Di Pascoli M, Verardo A, Gatta A . Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis. World J Gastroenterol. 2014; 20(10):2555-63. PMC: 3949264. DOI: 10.3748/wjg.v20.i10.2555. View

19.

Tana C, Ballestri S, Ricci F, Di Vincenzo A, Ticinesi A, Gallina S . Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. Int J Environ Res Public Health. 2019; 16(17). PMC: 6747357. DOI: 10.3390/ijerph16173104. View

20.

Eipel C, Abshagen K, Vollmar B . Regulation of hepatic blood flow: the hepatic arterial buffer response revisited. World J Gastroenterol. 2010; 16(48):6046-57. PMC: 3012579. DOI: 10.3748/wjg.v16.i48.6046. View